CN100455316C - 含有川芎的药物组合物在治疗慢性脑供血不足中的应用 - Google Patents
含有川芎的药物组合物在治疗慢性脑供血不足中的应用 Download PDFInfo
- Publication number
- CN100455316C CN100455316C CNB2004100198288A CN200410019828A CN100455316C CN 100455316 C CN100455316 C CN 100455316C CN B2004100198288 A CNB2004100198288 A CN B2004100198288A CN 200410019828 A CN200410019828 A CN 200410019828A CN 100455316 C CN100455316 C CN 100455316C
- Authority
- CN
- China
- Prior art keywords
- parts
- radix
- rhizoma
- blood supply
- herba
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 230000001684 chronic effect Effects 0.000 title claims abstract description 32
- 230000036770 blood supply Effects 0.000 title claims abstract description 29
- 210000004556 brain Anatomy 0.000 title abstract description 18
- 239000000203 mixture Substances 0.000 title abstract description 4
- 241000112528 Ligusticum striatum Species 0.000 title 1
- 230000007812 deficiency Effects 0.000 title 1
- 239000003814 drug Substances 0.000 claims abstract description 28
- 208000012886 Vertigo Diseases 0.000 claims abstract 2
- 231100000889 vertigo Toxicity 0.000 claims abstract 2
- 230000002490 cerebral effect Effects 0.000 claims description 34
- 239000008194 pharmaceutical composition Substances 0.000 claims description 17
- 241000628997 Flos Species 0.000 claims description 14
- 229940079593 drug Drugs 0.000 claims description 8
- 239000000796 flavoring agent Substances 0.000 claims description 8
- 235000019634 flavors Nutrition 0.000 claims description 8
- 238000002360 preparation method Methods 0.000 claims description 8
- 235000014435 Mentha Nutrition 0.000 claims description 7
- 241001072983 Mentha Species 0.000 claims description 7
- 241000545442 Radix Species 0.000 claims description 7
- 241001180876 Saposhnikovia Species 0.000 claims description 7
- 208000014644 Brain disease Diseases 0.000 claims 1
- 208000032274 Encephalopathy Diseases 0.000 claims 1
- 241000700159 Rattus Species 0.000 abstract description 31
- 230000006386 memory function Effects 0.000 abstract description 8
- 210000001168 carotid artery common Anatomy 0.000 abstract description 5
- 208000002173 dizziness Diseases 0.000 description 26
- 239000007788 liquid Substances 0.000 description 25
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 17
- 208000024891 symptom Diseases 0.000 description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- 238000011534 incubation Methods 0.000 description 12
- 230000000694 effects Effects 0.000 description 11
- 230000017531 blood circulation Effects 0.000 description 10
- 206010065559 Cerebral arteriosclerosis Diseases 0.000 description 9
- 201000005851 intracranial arteriosclerosis Diseases 0.000 description 9
- 238000003756 stirring Methods 0.000 description 8
- UIAGMCDKSXEBJQ-IBGZPJMESA-N 3-o-(2-methoxyethyl) 5-o-propan-2-yl (4s)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical group COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)[C@H]1C1=CC=CC([N+]([O-])=O)=C1 UIAGMCDKSXEBJQ-IBGZPJMESA-N 0.000 description 7
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 239000007864 aqueous solution Substances 0.000 description 6
- 125000003118 aryl group Chemical group 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 238000004821 distillation Methods 0.000 description 6
- 239000000706 filtrate Substances 0.000 description 6
- 230000035939 shock Effects 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- 206010019233 Headaches Diseases 0.000 description 5
- 230000003727 cerebral blood flow Effects 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 230000004087 circulation Effects 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 231100000869 headache Toxicity 0.000 description 5
- 206010020772 Hypertension Diseases 0.000 description 4
- 206010061216 Infarction Diseases 0.000 description 4
- 241001484259 Lacuna Species 0.000 description 4
- 206010008118 cerebral infarction Diseases 0.000 description 4
- 208000026106 cerebrovascular disease Diseases 0.000 description 4
- 210000001320 hippocampus Anatomy 0.000 description 4
- 230000007574 infarction Effects 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 229960000715 nimodipine Drugs 0.000 description 4
- 206010040560 shock Diseases 0.000 description 4
- 230000002792 vascular Effects 0.000 description 4
- 206010003694 Atrophy Diseases 0.000 description 3
- 102000009660 Cholinergic Receptors Human genes 0.000 description 3
- 108010009685 Cholinergic Receptors Proteins 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 206010063452 arteriosclerotic retinopathy Diseases 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 238000009835 boiling Methods 0.000 description 3
- 229940126678 chinese medicines Drugs 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 230000000302 ischemic effect Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000001537 neural effect Effects 0.000 description 3
- 230000010412 perfusion Effects 0.000 description 3
- 238000001556 precipitation Methods 0.000 description 3
- 238000004321 preservation Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- -1 stir Substances 0.000 description 3
- 206010012289 Dementia Diseases 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 208000032109 Transient ischaemic attack Diseases 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 230000037444 atrophy Effects 0.000 description 2
- 230000002146 bilateral effect Effects 0.000 description 2
- 210000001715 carotid artery Anatomy 0.000 description 2
- 210000004720 cerebrum Anatomy 0.000 description 2
- 238000003759 clinical diagnosis Methods 0.000 description 2
- 230000001447 compensatory effect Effects 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000007850 degeneration Effects 0.000 description 2
- 210000001652 frontal lobe Anatomy 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000003340 mental effect Effects 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 201000010875 transient cerebral ischemia Diseases 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 241000345998 Calamus manan Species 0.000 description 1
- 206010008097 Cerebral circulatory failure Diseases 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 229940122041 Cholinesterase inhibitor Drugs 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 201000006559 Vertebrobasilar insufficiency Diseases 0.000 description 1
- KUQFEFIFTUHBJE-UHFFFAOYSA-N [Cl].C=1C=CSC=1 Chemical compound [Cl].C=1C=CSC=1 KUQFEFIFTUHBJE-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000702 anti-platelet effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- 210000001841 basilar artery Anatomy 0.000 description 1
- 201000010861 basilar artery insufficiency Diseases 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000003925 brain function Effects 0.000 description 1
- 210000000269 carotid artery external Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- RNFNDJAIBTYOQL-UHFFFAOYSA-N chloral hydrate Chemical compound OC(O)C(Cl)(Cl)Cl RNFNDJAIBTYOQL-UHFFFAOYSA-N 0.000 description 1
- 229960002327 chloral hydrate Drugs 0.000 description 1
- 239000000544 cholinesterase inhibitor Substances 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 238000002591 computed tomography Methods 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 229940111134 coxibs Drugs 0.000 description 1
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 201000005577 familial hyperlipidemia Diseases 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 230000009191 jumping Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 210000000274 microglia Anatomy 0.000 description 1
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 230000004783 oxidative metabolism Effects 0.000 description 1
- 230000036284 oxygen consumption Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 235000012950 rattan cane Nutrition 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 201000009570 retrograde amnesia Diseases 0.000 description 1
- 238000000518 rheometry Methods 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001186 vagus nerve Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 210000004885 white matter Anatomy 0.000 description 1
Abstract
Description
Claims (5)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2004100198288A CN100455316C (zh) | 2004-06-30 | 2004-06-30 | 含有川芎的药物组合物在治疗慢性脑供血不足中的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2004100198288A CN100455316C (zh) | 2004-06-30 | 2004-06-30 | 含有川芎的药物组合物在治疗慢性脑供血不足中的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1714850A CN1714850A (zh) | 2006-01-04 |
CN100455316C true CN100455316C (zh) | 2009-01-28 |
Family
ID=35821211
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB2004100198288A Active CN100455316C (zh) | 2004-06-30 | 2004-06-30 | 含有川芎的药物组合物在治疗慢性脑供血不足中的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN100455316C (zh) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101919968A (zh) * | 2009-06-09 | 2010-12-22 | 太极集团有限公司 | 一种治疗头痛的中药组合物的新用途 |
CN109288972A (zh) * | 2018-10-16 | 2019-02-01 | 李文本 | 一种中药组合物 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1187994A (zh) * | 1997-01-13 | 1998-07-22 | 中美合资四川太极制药有限公司 | 一种用于治疗头痛的药物及其制备工艺 |
-
2004
- 2004-06-30 CN CNB2004100198288A patent/CN100455316C/zh active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1187994A (zh) * | 1997-01-13 | 1998-07-22 | 中美合资四川太极制药有限公司 | 一种用于治疗头痛的药物及其制备工艺 |
Non-Patent Citations (2)
Title |
---|
养血清脑颗粒治疗慢性脑供血不足的疗效观察. 李达仁.中药材,第26卷第9期. 2003 |
养血清脑颗粒治疗慢性脑供血不足的疗效观察. 李达仁.中药材,第26卷第9期. 2003 * |
Also Published As
Publication number | Publication date |
---|---|
CN1714850A (zh) | 2006-01-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20100112107A1 (en) | Plant extract compositions for affecting sleep | |
CN1872329A (zh) | 一种含有人参药物组合物在制备治疗慢性脑供血不足药物中的应用 | |
CN100592918C (zh) | 一种含有五味子药物组合物在制备治疗慢性脑供血不足药物中的应用 | |
CN1872214B (zh) | 一种含有羌活药物组合物在制备治疗慢性脑供血不足药物中的应用 | |
CN1872287A (zh) | 一种含有天麻药物组合物在制备治疗慢性脑供血不足药物中的应用 | |
CN100455316C (zh) | 含有川芎的药物组合物在治疗慢性脑供血不足中的应用 | |
CN1872081B (zh) | 一种葛根黄酮在制备治疗慢性脑供血不足药物中的应用 | |
CN1872187B (zh) | 一种含有黄芪药物组合物在制备治疗慢性脑供血不足药物中的应用 | |
CN1872276B (zh) | 含有黄芪提取物药物组合物在制备治疗慢性脑供血不足药物中的应用 | |
CN100411652C (zh) | 一种药物组合物在制备治疗慢性脑供血不足药物中的应用 | |
CN100548362C (zh) | 一种含有白附子药物组合物在制备治疗慢性脑供血不足药物中的应用 | |
CN1872213B (zh) | 一种含有桃仁药物组合物在制备治疗慢性脑供血不足药物中的应用 | |
CN1872297B (zh) | 一种含有广枣的药物组合物在制备治疗慢性脑供血不足的药物中的应用 | |
CN100563699C (zh) | 一种含有藳本的药物组合物在制备治疗慢性脑供血不足的药物中的应用 | |
CN1872319B (zh) | 一种含有远志的药物组合物在制备治疗慢性脑供血不足的药物中的应用 | |
WO2020233459A1 (zh) | 一种改善记忆的组合物及其制备方法 | |
CN100563692C (zh) | 一种含有磁石的药物组合物在制备治疗慢性脑供血不足的药物中的应用 | |
CN1872170B (zh) | 一种含有延胡索药物组合物在制备治疗慢性脑供血不足药物中的应用 | |
CN1872286B (zh) | 含有三七药物组合物在制备治疗慢性脑供血不足药物中的应用 | |
CN1872154B (zh) | 一种含有滇丹参药物组合物在制备治疗慢性脑供血不足药物中的应用 | |
CN1872291A (zh) | 一种含有钩藤药物组合物在制备治疗慢性脑供血不足药物中的应用 | |
CN1872178B (zh) | 一种含有白芍药物组合物在制备治疗慢性脑供血不足药物中的应用 | |
CN100450539C (zh) | 含有鹿茸的药物组合物在制备治疗慢性脑供血不足药物中的应用 | |
CN100563702C (zh) | 一种含有栀子的药物组合物在制备治疗慢性脑供血不足的药物中的应用 | |
CN100592911C (zh) | 一种含有vb6药物组合物在制备治疗慢性脑供血不足药物中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C56 | Change in the name or address of the patentee |
Owner name: TASLY PHARMACEUTICAL GROUP CO., LTD. Free format text: FORMER NAME: TIANJIN TASLY PHARMACEUTICAL CO., LTD. |
|
CP01 | Change in the name or title of a patent holder |
Address after: 300402, No. 1, Liaohe East Road, Beichen Science Park, Beichen District, Tianjin Patentee after: Tasly Pharmaceutical Group Co., Ltd. Address before: 300402, No. 1, Liaohe East Road, Beichen Science Park, Beichen District, Tianjin Patentee before: Tianjin Tianshili Pharmaceutical Co., Ltd. |
|
CP01 | Change in the name or title of a patent holder | ||
CP01 | Change in the name or title of a patent holder |
Address after: 300402, No. 1, Liaohe East Road, Beichen Science Park, Beichen District, Tianjin Patentee after: Tasly Pharmaceutical Group Limited by Share Ltd Address before: 300402, No. 1, Liaohe East Road, Beichen Science Park, Beichen District, Tianjin Patentee before: Tasly Pharmaceutical Group Co., Ltd. |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20191213 Address after: 117200 No. 1 Tianshili Avenue, Huanren Manchu Autonomous County, Benxi City, Liaoning Province Patentee after: Tianshili Northeast Modern Chinese Medicine Resources Co., Ltd. Address before: 300402, No. 1, Liaohe East Road, Beichen Science Park, Beichen District, Tianjin Patentee before: Tasly Pharmaceutical Group Limited by Share Ltd |